elacestrant: Clinical Trials

5 trials of elacestrant, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 recruiting, 1 active not recruiting, 1 completed. 5 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 35Recruiting 3, Active not recruiting 1, Completed 1

Follow elacestrant: new trials by email Literature Review of elacestrant trials Research Report on elacestrant

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC
Elacestrant, Standard-of-care endocrine treatment - Breast Cancer, HR+/HER2- Breast Cancer
Phase 3RecruitingWomen's Cancer Study Group GmbH15202026-04-292026-08-07
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
Everolimus, Elacestrant, Placebo - Advanced Breast Cancer, ER-positive Breast Cancer
Phase 3RecruitingMedSIR3002024-12-052026-08-24
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Elacestrant, Anastrozole, Letrozole - Breast Cancer
Phase 3Active not recruitingStemline Therapeutics, Inc.45562024-09-272026-11-04
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
Elacestrant, Tamoxifen, Letrozole 2.5mg - ER-positive Breast Cancer, HER2-negative Breast Cancer
Phase 3RecruitingEuropean Organisation for Research and Treatment of Cancer - EORTC2202023-12-152026-10-07
Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Elacestrant, Standard of Care - Breast Cancer
Phase 3CompletedStemline Therapeutics, Inc.4782019-05-102025-09-15

Conditions studied

Breast Neoplasms (4)  ·  Breast Neoplasms, Male (1)

Sponsors

Stemline Therapeutics, Inc. (2)  ·  European Organisation for Research and Treatment of Cancer - EORTC (1)  ·  MedSIR (1)  ·  Women's Cancer Study Group GmbH (1)

Countries

France (4)  ·  Germany (4)  ·  Italy (4)  ·  Spain (4)  ·  Austria (3)  ·  Belgium (3)  ·  Greece (3)  ·  Portugal (3)  ·  United Kingdom (3)  ·  Argentina (2)  ·  Australia (2)  ·  Brazil (2)  ·  Canada (2)  ·  Czechia (2)  ·  Denmark (2)

Top investigators

Antonio Llombart-Cussac, M.D., Ph.D. (1)  ·  Emmanouil Saloustros (1)  ·  Michail Ignatiadis (1)  ·  Monika Graeser, PD Dr (1)  ·  NAdia Harbeck, Prof Dr (1)  ·  Oleg Gluz, Prof Dr (1)  ·  Peter Schmid, PHD Dr (1)  ·  Sherko Kuemmel, Prof Dr (1)

Results publications

PMID 31426673, PMID 35584336, PMID 38381994

NIH funding

2025 (1)